Get the Stockscreener App
0.6693
2.18%
0.0143
After Hours:
.67
0.0007
+0.10%
X 4 Pharmaceuticals Inc stock is traded at $0.6693, with a volume of 264.15K.
It is up +2.18% in the last 24 hours and down -4.39% over the past month.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$0.655
Open:
$0.655
24h Volume:
264.15K
Relative Volume:
0.15
Market Cap:
$110.37M
Revenue:
-
Net Income/Loss:
$-101.17M
P/E Ratio:
-0.6436
EPS:
-1.04
Net Cash Flow:
$-96.57M
1W Performance:
-5.21%
1M Performance:
-4.39%
6M Performance:
-51.85%
1Y Performance:
-38.60%
1-Day Range:
$0.655
$0.677
1-Week Range:
$0.6428
$0.73
52-Week Range:
$0.5311
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Have you been able to find a good deal on X4 Pharmaceuticals Inc’s shares? - US Post News
Advanced Drug Delivery Systems Market Advancements Highlighted by Size, Trends, Drivers And Forecast To 2033 - WhaTech
Ensign Peak Advisors Inc Grows Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Why Investors Shouldn't Be Surprised By Universe Pharmaceuticals INC's (NASDAQ:UPC) 92% Share Price Plunge - Simply Wall St
Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues - Simply Wall St
Bank of New York Mellon Corp Has $272,000 Stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Insider’s View: Deciphering X4 Pharmaceuticals Inc (XFOR)’s Financial Health Through Ratios - The Dwinnex
The time has not yet come to remove your chips from the table: X4 Pharmaceuticals Inc (XFOR) - SETE News
B. Riley Securities gives a Neutral recommendation for X4 Pharmaceuticals Inc (XFOR) - Knox Daily
Taking a Closer Look At Esperion Therapeutics Inc. (ESPR) Following Its Recent Trade - Knox Daily
Ovintiv Inc [OVV] stock was sold by Mayson Howard John at the price of US$0.2 million - Knox Daily
Lawmakers challenge drug company CEO over steep prices for Ozempic and Wegovy - PBS NewsHour
Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4) - Quantisnow
Autism Spectrum Disorders Treatment Market Outlook: Current Therapies, Emerging Treatments, and Global Grow... - WhaTech
Nasal Drug Delivery Technology Market: Revolutionizing Healthcare Delivery with Innovations and Projected M... - WhaTech
Are X4 Pharmaceuticals Inc’shares a good deal? - US Post News
K2 Principal Fund L.P. Invests $284,000 in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Simply Wall St
Perennial Allergic Rhinitis Drug Industry Growth Factors, Applications, and Forecast by (2024-2034) - KnowCasino
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Treating Eye Pressure: Ocular Hypertension Treatment Market Insights 2024 - WhaTech
Perennial Allergic Rhinitis Drug Industry Growth Factors, Applications, and Forecast by (2024-2034) - La Funcion mx
BioAtla and Context Therapeutics Announce Exclusive - GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - Yahoo Finance
Muscarinic Acetylcholine Receptor Market Advancements Highlighted by Report 2024: Global Size, Share, Growt... - WhaTech
Fragile X held him back. An experimental drug is helping him break free - NPR
X-Linked Retinitis Pigmentosa Market Size is Set for Rapid - openPR
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Brazil court asks X for documents as the platform starts to comply with orders - Yahoo Finance
2024 Vision: Dry Eye Syndrome Market Innovation and Growth - WhaTech
Director Singleton J Matthew exercised 10,300 shares at a strike of $1.19 and sold $715,850 worth of shares (10,300 units at $69.50) (SEC Form 4) - Quantisnow
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price - Simply Wall St
BMO maintains Outperform rating on C4 Therapeutics shares - Investing.com
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51% - Yahoo Finance
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market 2024 To Reach $2.33 Billion By 2028 At Rate Of - EIN News
X4 Pharmaceuticals Inc Inc. (XFOR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Top investors say X4 Pharmaceuticals Inc (XFOR) ticks everything they need - SETE News
Xaar revenue slides in first half - Printweek
Unitedhealth Group Inc [UNH] Stock sold by Insider ROOS THOMAS E for $1.62 million - Knox Daily
Xaar innovation combats legacy ceramics slump as company charts bounceback - Business Weekly
Xaar swings to loss in challenging first half - ShareCast
Xaar plc Navigates Market Challenges with New Growth - TipRanks
Xaar: Progressive - Vox Markets
Should investors be concerned about X4 Pharmaceuticals Inc (XFOR)? - US Post News
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Market Watch: X4 Pharmaceuticals Inc (XFOR)’s Noteworthy Gain, Closing at 0.71 - The Dwinnex
Biopharma Layoff Tracker 2024: Oncternal, Biosense Webster, Charles River Laboratories and More Cut Staff - BioSpace
United States Intravenous Iron Drug Market By Application - Third Eye News
North America Medulloblastoma Drug Market By Application – news - Vaccine Storage & Packaging ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by TD Asset Management Inc - Defense World
North America Drug Discovery Outsourcing Market Size USD 3.4 Bn in 2023| CAGR of 7.2%| USD 5.93 Bn by 2032 - Third Eye News
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):